The acute myeloid leukemia therapeutics market is expected to grow at a CAGR of 28.4% from 2015 to 2020. The acute myeloid leukemia market has been studied on the basis of current regimens and drugs and pipeline (phase III) drugs. The market was dominated by AVD regimen in 2010. However, by 2020; the market is expected to be dominated by AVD regimen and Cytrabine. AVD regimen is used for the treatment of acute promyelocytic leukemia, which is a type of acute myeloid leukemia. Cyatarabine is used for the treatment of patients suffering from relapse of acute myeloid leukemia. The market is expected to be dominated by pipeline drug, Quizartinib in 2020. Pipeline drug and increasing acute myeloid leukemia population globally are major factors driving the market for new drugs.

From a regional approach, North America accounts for the largest chronic lymphocytic leukemia population globally. The incidence rate and mortality rate for acute myeloid leukemia is showing upward trend due to the increase in the aging population in most of the developed countries. Males and females above 50 years of age are at high risk for acute myeloid leukemia. The incidence rate and mortality rate for acute myeloid leukemia are showing an upswing due to the increase in the aging population in most of the developed countries. Such an upward incidence trend can be attributed to the age risk factor of chronic lymphocytic leukemia. Recent studies show that males and females above 65 years of age are at high risk for acute myeloid leukemia. Epidemiologic studies have found that incidence and mortality due to acute myeloid leukemia differ according to race and ethnicity. The incidence and mortality rates for acute myeloid leukemia are higher in whites than in people of the other racial and ethnic groups due to genetic factors.

The major players in the market include Ambit Biosciences Corporation (U.S.), Celgene Corporation (U.S.), Cephalon Inc. (U.S.), Clavis Pharma ASA (Norway), Eisai Co. Ltd (Japan), Genzyme Corporation (U.S.), and Sunesis Pharmaceuticals Inc. (U.S.).

About MarketsandMarkets

MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world. MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services.

MarketsandMarkets covers thirteen industry verticals, including advanced materials, automotives and transportation, banking and financial services, biotechnology, chemicals, consumer goods, energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals, semiconductor and electronics, and telecommunications and IT.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository. To know more about us and our reports, please visit our website www.marketsandmarkets.com

Note: An email containing the Login Details and Time of the Analyst Briefing will be sent to you soon after your registration.